Tempus AI

We now have over one million records with matched clinical and genomic data. This dataset is unique to Tempus and allows us to support the critical research and development of the next generation of cancer treatments. Explore our data offerings: https://tempus.co/3Sr1413

July is Minority Mental Health Month, a time to recognize and address the unique mental health challenges faced by minority communities. This month serves as a reminder to celebrate diversity, and advocate for equitable mental health care. Explore our offerings to bring personalized medicine to mental health: https://tempus.co/3zSxZoC

A recent case study highlights the implementation of Tempus Next at St. Francis Hospital and Heart Center to identify patients with severe Aortic Stenosis (AS) who had not previously been receiving guideline-recommended care. Tempus Next uses AI, including natural language processing, to contextualize patients in real-time using precise patient screening parameters to identify potentially undertreated or untreated patients. Read on: https://tempus.co/3Yb0gRB

We've created one of the world’s largest libraries of human ex vivo tumor organoids with rich clinical and molecular characterization. We're now offering our biopharma customers an opportunity to screen their pre-clinical candidates against 60 organoids that span 10 different cancer indications, and rapidly generate multimodal data to inform drug development programs. To learn more, click here: https://tempus.co/3WvYKbC

Join us for an upcoming webinar, "Integrating Omics in R&D: A new era of biomedical research,” on July 31 at 11 AM CT. Speakers Nike Beaubier, MD, Calvin Chao, MD, and Dr. M. Sharon Stack, PhD will discuss the transformative role of multi-omics in understanding complex disease mechanism and will dive into the integration of diverse omics data, from NGS to proteomics, in research. Register here: https://tempus.co/3Y8HGcK

We’re excited to announce that our multimodal immune profile score (IPS) algorithmic test is now available for RUO. IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. IPS is a pan-cancer, laboratory developed test that assesses a combination of immunotherapy-related biomarkers from prior DNA and RNA test results to calculate an IPS from 0-100 and a classification of either IPS-Low or IPS-High. Learn more: https://tempus.co/3y7ylHp

We’re looking for a Molecular Technologist to join our laboratory team in Chicago. The role will work with a cutting-edge genomics workflow to provide high-quality next-generation sequencing data with rapid turnaround times in a clinical laboratory. Learn more and apply here: https://tempus.co/3zKkqru #NowHiring #ChicagoJobs

We’re excited to share that we have reached a major milestone of publishing our 500th publication. In the last eight years, we have invested in rigorous scientific research to validate our diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by our multimodal data library. Learn more: https://tempus.co/462AT68

We’re excited to announce that our PurIST℠ algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurIST℠ PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from previously-sequenced, laboratory developed test (LDT), transcriptomic (RNA) data, representing a meaningful step towards reimbursement for AI-enabled algorithms. Learn more: https://tempus.co/3zx5QmZ

We’re excited to announce that the Centers for Medicare & Medicaid Services has granted Advanced Diagnostic Laboratory Test (ADLT) status for our xT CDx test. xT CDx is the first FDA-approved next-generation sequencing assay to perform matched normal sequence analysis to provide tumor mutation profiling for patients with solid organ neoplasms. Learn more: https://tempus.co/3L9vnVO